S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
NASDAQ:AGLE

Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News

$11.86
+0.19 (+1.63%)
(As of 09/22/2023 ET)
Compare
Today's Range
$11.57
$12.72
50-Day Range
$10.86
$16.92
52-Week Range
$2.66
$39.00
Volume
52,216 shs
Average Volume
107,846 shs
Market Capitalization
$48.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.38

Aeglea BioTherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
105.5% Upside
$24.38 Price Target
Short Interest
Healthy
1.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.95) to ($1.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

485th out of 967 stocks

Pharmaceutical Preparations Industry

209th out of 443 stocks


AGLE stock logo

About Aeglea BioTherapeutics (NASDAQ:AGLE) Stock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

AGLE Price History

AGLE Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Aeglea Biotherapeutics (AGLE) Gets a Buy from Stifel Nicolaus
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Aeglea BioTherapeutics Announces Reverse Stock Split
Aeglea BioTherapeutics Appoints Scott Burrows As Chief Financial Officer
Aeglea BioTherapeutics (NASDAQ: AGLE)
Funding wrap: Former Dell Med dean raises $30M
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Company Calendar

Last Earnings
8/11/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.38
High Stock Price Forecast
$37.50
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+105.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-83,820,000.00
Net Margins
-22,195.36%
Pretax Margin
-22,209.53%

Debt

Sales & Book Value

Annual Sales
$2.33 million
Book Value
$20.45 per share

Miscellaneous

Free Float
3,918,000
Market Cap
$48.03 million
Optionable
Optionable
Beta
2.53
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Jonathan D. Alspaugh M.B.A. (Age 40)
    Pres, CFO & Principal Accounting Officer
    Comp: $568.55k
  • Mr. James Paul Kastenmayer J.D. (Age 51)
    Ph.D., Consultant
    Comp: $611.84k
  • Dr. Cameron Turtle DPHIL (Age 33)
    Ph.D., Chief Operating Officer
  • Joey Perrone
    VP of Fin. & Investor Relations
  • Dr. Kelly Boothe Ph.D.
    Sr. Director of Corp. Communications & Investor Relations
  • Ms. Cortney Caudill M.B.A.
    Chief Product Officer













AGLE Stock - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price forecast for 2023?

6 brokerages have issued 12 month target prices for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $12.50 to $37.50. On average, they anticipate the company's stock price to reach $24.38 in the next year. This suggests a possible upside of 105.5% from the stock's current price.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How have AGLE shares performed in 2023?

Aeglea BioTherapeutics' stock was trading at $11.2475 at the beginning of 2023. Since then, AGLE shares have increased by 5.4% and is now trading at $11.86.
View the best growth stocks for 2023 here
.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 61,600 shares, a decrease of 96.1% from the August 15th total of 1,570,000 shares. Based on an average daily trading volume, of 256,400 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the shares of the stock are sold short.
View Aeglea BioTherapeutics' Short Interest
.

When is Aeglea BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGLE earnings forecast
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its earnings results on Friday, August, 11th. The biotechnology company reported ($41.50) earnings per share for the quarter, missing analysts' consensus estimates of ($4.50) by $37.00. The biotechnology company earned $0.69 million during the quarter. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%.

When did Aeglea BioTherapeutics' stock split?

Shares of Aeglea BioTherapeutics reverse split before market open on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include VR Adviser LLC (9.70%), Affinity Asset Advisors LLC (7.49%), Driehaus Capital Management LLC (7.10%), Commodore Capital LP (4.45%), Goldman Sachs Group Inc. (0.85%) and BlackRock Inc. (0.81%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends
.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $11.86.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $48.03 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($71.00) on an earnings per share basis.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.

This page (NASDAQ:AGLE) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -